Table 3.

Anaphylactic reaction and anaphylactic shock cases per 10⁶ mRNA COVID-19 vaccine doses in children 5–17 years of age by vaccine and age group, EudraVigilance (as of October 8, 2022).

Vaccine	mRNA-1273a	BNT162b2b	Total
Anaphylactic reaction cases / 106 doses (95% CI)
5–9 years	0.00 (0.00–0.00)	8.32 (5.80–10.83)	8.32 (5.80–10.83)
10–17 years	9.29 (4.24–14.33)	10.56 (9.21–11.92)	10.49 (9.18–11.80)
Total	9.28 (4.24–14.33)	10.15 (8.95–11.35)	10.10 (8.94–11.27)
Anaphylactic shock cases / 106doses (95% CI)
5–9 years	0.00 (0.00–0.00)	1.19 (0.24–2.14)	1.19 (0.24–2.14)
10–17 years	2.86 (0.06–5.66)	3.04 (2.31–3.77)	3.03 (2.32–3.73)
Total	2.86 (0.06–5.66)	2.69 (2.08–3.31)	2.70 (2.10–3.30)

CI: confidence interval.

^aSpikevax (Moderna).

^bComirnaty (Pfizer-BioNTech).